ARLINGTON, Virginia., June 16, 2021 / PRNewswire / – Today the American Diabetes Association® (ADA) released important updates to the Standards of Care for Diabetes 2021 in annotations as Living Standards of Care. The changes include new data on teplizumab and SGLT2 inhibitors, as well as the effects of drugs on patients with chronic kidney disease. These changes were driven by recently published research and were drawn up and approved by the ADA’s Professional Practice Committee, which is responsible for creating the Standards of Care. Updates to Section 10, Cardiovascular Disease and Risk Management, have also been reviewed and approved by the American College of Cardiology, which endorses this section. The Living Standards of Care are now available online at Diabetes Care®.
Updates to the living standards of care include information added to the following sections:
- Section 2. Classification and Diagnosis of Diabetes was revised to include evidence from a study of the anti-CD3 antibody teplizumab in relatives at risk for type 1 diabetes that showed a delay in the development of type I diabetes.
- Section 10. Cardiovascular Disease and Risk Management were updated to reflect new evidence from cardiovascular studies, including the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV), the effect of sotagliflozin on cardiovascular and renal events in patients with Type 2 Diabetes, Include and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED), the Empagliflozin Outcome Study in Patients with Chronic Heart Failure and Reduced Ejection Fraction (EMPEROR-reduced), and the Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Study of Worsening Heart Failure (SOLOIST-WHF).
- Section 11. Microvascular Complications and Foot Care was modified to include the new evidence from studies of drugs that affect patients with chronic kidney disease: the Dapagliflozin Study in Patients with Chronic Kidney Disease (DAPA-CKD) and the Finerenone Reduction Study of kidney failure and disease progression in the study on diabetic kidney disease (FIDELIO-DKD).
“There have been so many exciting advances in diabetes that we are posting updates on the Standards of Care more frequently. We pride ourselves on the work of our exceptional team of experts,” Robert Gabbay, Chief Scientific and Medical Officer of ADA. “The American Diabetes Association is committed to improving the lives of everyone with diabetes through this publication of the most respected guidelines for diabetes care professionals, and updates like this are part of that commitment.”
The standards of care provide the latest comprehensive, evidence-based recommendations for the diagnosis and treatment of children and adults with type 1, type 2 or gestational diabetes; Strategies to improve the prevention or delay of type 2 diabetes; and therapeutic approaches that reduce complications and positively influence health outcomes. In 2018, the ADA began updating and revising the online version of the Standards of Care year-round, with annotations for new evidence or regulatory changes that deserve immediate inclusion. The online version of the Care Standards now includes any research updates or policy changes approved during the course of 2021.
The full, commented standards of care, including updates made today, are available online at Diabetes Care. The abridged standards of medical care for diabetes have also been updated and are available online at Clinical Diabetes.
Via the American Diabetes Association
More than 4,000 people are newly diagnosed with diabetes in America every day. More than 122 million Americans have diabetes or prediabetes and struggle to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation’s leading voluntary health organization dedicated to helping people overcome the diabetes epidemic and help people with diabetes thrive. For 80 years, the ADA has advanced discovery and research into the treatment, treatment, and prevention of diabetes while working tirelessly to find a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education to improve their quality of life. Diabetes brought us together. What we do next will make us connected for life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Get involved with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).
SOURCE American Diabetes Association
similar links
https://www.diabetes.org
